Tryngolza Shows Efficacy in Severe Hypertriglyceridemia

Tryngolza Shows Strong Efficacy in Severe Hypertriglyceridemia Phase III

Sobi and Ionis Pharmaceuticals' Tryngolza (olezarsen) demonstrated significant efficacy in a pooled subgroup analysis of its pivotal Phase III CORE and CORE2 studies for severe hypertriglyceridemia. Patients with triglyceride levels of 10 mmol/L or more taking an 80mg dose experienced a 66% placebo-adjusted drop in blood fatty acid levels at six months, while those on 50mg saw a 59% reduction. Overall, 85% of Tryngolza-treated patients achieved triglyceride levels below 10 mmol/L, significantly reducing the risk of acute pancreatitis by 85%. These results were presented at the 2026 EAS congress, as the companies await US and European regulatory decisions, with an FDA target action date of June 30.

• Significant Triglyceride Reduction: In a pooled analysis of Phase III CORE and CORE2 studies, Tryngolza (olezarsen) achieved substantial reductions in triglyceride levels. Patients with severe hypertriglyceridemia (≥10 mmol/L) receiving an 80mg four-weekly dose experienced a 66% placebo-adjusted drop in blood fatty acid levels at six months, while a 50mg dose led to a 59% reduction. This demonstrates the drug's potent lipid-lowering effect.
• Reduced Acute Pancreatitis Risk: The treatment significantly lowered the risk of acute pancreatitis by 85% in patients with severe hypertriglyceridemia. Furthermore, 85% of patients treated with Tryngolza achieved triglyceride levels below 10 mmol/L, a critical threshold recommended by the European Atherosclerosis Society for urgent intervention to prevent acute pancreatitis. This highlights Tryngolza's potential as a preventative measure.
• Regulatory Milestones and Market Outlook: Sobi and Ionis are actively pursuing regulatory approvals for Tryngolza in severe hypertriglyceridemia, with the US FDA having a target action date of June 30. The drug is already approved for familial chylomicronaemia syndrome (FCS). GlobalData predicts blockbuster status for Tryngolza by 2029, indicating strong market potential despite competition from Arrowhead's Redemplo.

Tryngolza's Pivotal Phase III Efficacy in Severe Hypertriglyceridemia

Recent meta-analyses of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III, demonstrate substantial efficacy in severe hypertriglyceridemia across multiple randomized controlled trials. A comprehensive meta-analysis of six RCTs involving 2,676 participants showed dose-dependent triglyceride reductions of 46.61% with the 50 mg dose and 54.37% with the 80 mg dose (both p<0.0001). In patients with non-familial chylomicronemia syndrome, triglyceride levels decreased by 59.95% at six months. Beyond triglyceride reduction, olezarsen significantly decreased apolipoprotein C-III levels by approximately 64-67% across dosing regimens, reduced non-HDL cholesterol by 21-25%, and lowered remnant cholesterol by 55%.

The most clinically significant finding relates to acute pancreatitis prevention, with olezarsen reducing the incidence from 8.7% in placebo groups to 1.2% in treated patients (RR 0.14, 95% CI 0.07-0.29). This represents an 84% relative risk reduction for acute pancreatitis, a life-threatening complication of severe hypertriglyceridemia. The 50 mg dose showed particularly robust pancreatitis prevention (RR 0.16), while maintaining substantial triglyceride reduction efficacy. Network meta-analyses positioning olezarsen 80 mg every four weeks as having the highest ranking for triglyceride reduction among apolipoprotein C-III inhibitors further validate its therapeutic potential.

Safety profiles across these studies demonstrate that olezarsen is generally well-tolerated, with adverse event rates comparable to placebo in most analyses. However, the 80 mg dose showed increased risk of transaminase elevations (ALT/AST ≥3× upper limit of normal, RR 2.56), suggesting the need for hepatic monitoring at higher doses. Serious adverse events were more frequent than placebo in some studies, though the overall safety profile remains acceptable. These findings support olezarsen as a promising therapeutic option for severe hypertriglyceridemia management, particularly given its dual benefit of triglyceride reduction and pancreatitis prevention.

Designing CORE and CORE2 for Severe Hypertriglyceridemia Patients

Recent Phase 3 trials for severe hypertriglyceridemia have employed diverse study designs to evaluate novel therapeutic approaches. These trials have generally focused on patients with triglyceride levels ≥500 mg/dL, with primary endpoints centered on triglyceride reduction and secondary endpoints examining cardiovascular outcomes and safety parameters.

Navigating the Competitive Landscape for Severe Hypertriglyceridemia

Published studies reveal that standard-of-care treatments for severe hypertriglyceridemia rely primarily on lipid-lowering agents, while investigational therapies focus on novel mechanisms and emergency interventions. Comparative data demonstrates varying efficacy across different therapeutic approaches, though direct head-to-head trials remain limited.

• Standard pharmacologic therapies include fibrates (fenofibrate, gemfibrozil), niacin, omega-3 fatty acids, and statins, each reducing triglyceride levels by approximately 10-50%, with fibrates considered the current drugs of choice for hypertriglyceridemia

• Volanesorsen, a second-generation antisense oligonucleotide targeting apolipoprotein C3, showed dramatic efficacy in a familial chylomicronemia syndrome patient, reducing triglyceride levels from >5000 mg/dL to 350-500 mg/dL at 12 months while eliminating need for lipoprotein apheresis

• Therapeutic plasma exchange and plasmapheresis provide rapid triglyceride reduction in emergency settings when standard therapies fail, particularly for acute pancreatitis with severe hypertriglyceridemia (>1000 mg/dL), achieving levels well below 1000 mg/dL

• Self-monitoring approaches using lipid measurement devices demonstrated sustained triglyceride control in 32 patients, with no severe hypertriglyceridemia (>750 mg/dL) observed during 48-week monitoring periods and improved dietary compliance

• Novel antisense oligonucleotides and ANGPTL3/4 inhibitors target proteins that inhibit lipoprotein lipase activity, offering promise through LPL-independent pathways, though thrombocytopenia remains a notable adverse effect requiring monitoring

• Clinical outcome data remains limited, as no triglyceride-lowering pharmacological strategy has conclusively demonstrated ability to modify clinical endpoints, highlighting the need for ongoing comparative effectiveness research

Olezarsen's Pivotal Data: A New Standard for Severe Hypertriglyceridemia

The latest Phase III data for olezarsen (Tryngolza) marks a pivotal moment in the management of severe hypertriglyceridemia (HTG), particularly for individuals grappling with extremely high triglyceride levels (≥10 mmol/L). This patient population faces a critical and often life-threatening risk of acute pancreatitis, a complication that traditional lipid-lowering therapies have struggled to effectively mitigate. The impressive 66% placebo-adjusted reduction in triglycerides with the 80mg dose, coupled with an 85% reduction in acute pancreatitis risk, underscores olezarsen's potential to transform care for these high-risk patients.

As an antisense oligonucleotide targeting apolipoprotein C-III (APOC3), olezarsen works by inhibiting a key regulator of triglyceride metabolism, thereby enhancing the clearance of triglyceride-rich lipoproteins. This targeted approach has already led to its approval for Familial Chylomicronemia Syndrome (FCS), a rare genetic disorder. The new data, however, suggests a much broader utility, positioning olezarsen as a leading candidate for the wider severe HTG population, where effective treatment options are scarce. Its generally favorable safety profile, particularly when compared to earlier APOC3 inhibitors, further strengthens its appeal.

However, the journey for olezarsen is not without considerations. While the reduction in pancreatitis risk is substantial, the long-term impact on major atherosclerotic cardiovascular disease (ASCVD) events in the broader HTG population remains a critical area of ongoing investigation, notably in trials like Essence-TIMI 73b. Furthermore, while generally safe, clinicians will need to monitor for potential mild platelet count decreases and, at higher doses, transient elevations in liver enzymes. The competitive landscape is also dynamic, with other novel lipid-lowering agents emerging. Nevertheless, with regulatory decisions pending, olezarsen is poised to redefine the therapeutic paradigm for severe HTG, offering a powerful new tool to significantly reduce the burden of this challenging condition and its devastating complications.